Skip to content

Study · Randomized controlled trial · n = 92 · 2013

4 results

Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis.

Farahmand P, Marin F, Hawkins F, Möricke R, Ringe JD, Glüer CC, Papaioannou N, Minisola S, Martínez G, Nolla JM, Niedhart C, Guañabens N and 10 more

Show all authors

Nuti R, Martín-Mola E, Thomasius F, Peña J, Graeff C, Kapetanos G, Petto H, Gentzel A, Reisinger A, Zysset PK

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA6 Jun 2013Cited by 32 (Europe PMC)

PMID23740422 (opens in a new tab)PMCIDPMC3838582 (opens in a new tab)DOI10.1007/s00198-013-2379-5 (opens in a new tab)PepBankPUB-23740422
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In men with glucocorticoid-induced osteoporosis, PINP increased with teriparatide and decreased with risedronate.

    In plain wordsIn men with glucocorticoid-induced osteoporosis, a bone formation marker increased with teriparatide and decreased with risedronate.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSerum PINP
    Study

    n = 92

    Comparator
    Risedronate
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    PINP and CTx levels increased in the teriparatide group and decreased in the risedronate group.
    1 context sentence
    Summary · context
    A total of 92 men with GIO were included in an 18-month, randomized, open-label trial of teriparatide (20 μg/day, n = 45) and risedronate (35 mg/week, n = 47).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In men with glucocorticoid-induced osteoporosis, CTx increased with teriparatide and decreased with risedronate.

    In plain wordsIn men with glucocorticoid-induced osteoporosis, a bone resorption marker increased with teriparatide and decreased with risedronate.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSerum CTx
    Study

    n = 92

    Comparator
    Risedronate
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    PINP and CTx levels increased in the teriparatide group and decreased in the risedronate group.
    1 context sentence
    Summary · context
    A total of 92 men with GIO were included in an 18-month, randomized, open-label trial of teriparatide (20 μg/day, n = 45) and risedronate (35 mg/week, n = 47).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In men with glucocorticoid-induced osteoporosis, FEA-derived vertebral parameters increased in both groups but were significantly higher at 18 months with teriparatide than with risedronate.

    In plain wordsIn men with glucocorticoid-induced osteoporosis, calculated vertebral measures rose in both groups and were higher at 18 months with teriparatide than risedronate.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFEA-derived vertebral parameters at 18 months
    Study

    n = 92

    Comparator
    Risedronate
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    FEA-derived parameters increased in both groups, but were significantly higher at 18 months in the teriparatide group.
    2 context sentences
    Summary · context
    Stiffness and strength were computed for each model and loading mode.
    Summary · context
    A total of 92 men with GIO were included in an 18-month, randomized, open-label trial of teriparatide (20 μg/day, n = 45) and risedronate (35 mg/week, n = 47).

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 04HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther

    In teriparatide-treated men with glucocorticoid-induced osteoporosis, PINP changes correlated positively with FE strength changes.

    In plain wordsIn teriparatide-treated men, bone formation marker changes were linked to calculated vertebral strength changes.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePINP change and vertebral strength correlation
    Study

    n = 45

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Significant positive correlations were found between changes from baseline of PINP at 3, 6 and 18 months with changes in FE strength in the teriparatide-treated group, but not in the risedronate group.
    1 context sentence
    Summary · context
    A total of 92 men with GIO were included in an 18-month, randomized, open-label trial of teriparatide (20 μg/day, n = 45) and risedronate (35 mg/week, n = 47).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.